CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to OGN

Desloratadine 2.5 mg

Phase 2
Organon & Co. (OGN)

Phase 2

Development Phase

0

Upcoming Catalysts

0

Historical Events

9

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Post-nasal Drip

View Full Landscape
Drug Information

Target Indication

Post-nasal Drip

Clinical Trial

NCT00816972

Last updated: 2/13/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Regulatory Approvals
EMAPending

Desloratadine Krka

Relief of symptoms of allergic rhinitis and urticaria

View on EMA
EMA1/13/2012

Desloratadine ratiopharm

Desloratadine ratiopharm is indicated in adults for the relief of symptoms associated with: allergic rhinitis chronic idiopathic urticaria as initially diagnosed by a physician

View on EMA
EMA1/13/2012

Desloratadine Actavis

Treatment of allergic rhinitis and urticaria.

View on EMA
EMA11/28/2011

Dasselta

Dasselta is indicated for the relief of symptoms associated with: allergic rhinitis; urticaria.

View on EMA
EMA11/24/2011

Desloratadine Teva

Desloratadine Teva is indicated for the relief of symptoms associated with: allergic rhinitis; urticaria.

View on EMA
EMA1/15/2001

Allex

Aerius is indicated for the relief of symptoms associated with: allergic rhinitis (see section 5.1) urticaria (see section 5.1)

View on EMA
EMA1/15/2001

Neoclarityn

Neoclarityn is indicated for the relief of symptoms associated with: allergic rhinitis urticaria

View on EMA
EMA1/15/2001

Azomyr

Azomyr is indicated for the relief of symptoms associated with: allergic rhinitis (see section 5.1) urticaria (see section 5.1)

View on EMA
EMA1/15/2001

Opulis

Opulis is indicated for the relief of symptoms associated with:- allergic rhinitis (see section 5.1)- urticaria (see section 5.1)

View on EMA
Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.